智通财经APP获悉，生物技术公司TScan Therapeutics(TCRX.US)周四宣布，将出售约3000万美元的预融资认股权证，能以每股4.00美元的价格购买总计不超过750万 ...

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...

(RTTNews) - Shares of TScan Therapeutics, Inc. (TCRX), a clinical-stage biotechnology company specializing in T cell receptor-engineered therapies for cancer, are surging in premarket trading ...

TScan Therapeutics, Inc. (TCRX) has been on a downward spiral lately with significant selling pressure. After declining 5.6% over the past four weeks, the stock looks well positioned for a trend ...

TScan Therapeutics (TCRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vikram Purohit from Morgan Stanley maintained a Buy rating ...

TScan Therapeutics has entered a new loan agreement with Silicon Valley Bank, securing up to $52.5 million to refinance existing debt and fund corporate purposes. This non-dilutive financing ...